Next Article in Journal
Anastomosing Hemangioma of the Kidney: Radiologic and Pathologic Distinctions of a Kidney Cancer Mimic
Previous Article in Journal
Harmonization of PD-L1 Testing in Oncology: A Canadian Pathology Perspective
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 25
Issue 3
10.3747/co.25.3936
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Overcoming Resistance in a BRAF V600e–Mutant Adenocarcinoma of the Lung

by
T. Schmid
and
M. Buess
*
Department of Oncology, St. Claraspital, Kleinriehenstrasse 30, Basel 4016, Switzerland
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2018, 25(3), 217-219; https://doi.org/10.3747/co.25.3936
Submission received: 4 March 2018 / Revised: 6 April 2018 / Accepted: 9 May 2018 / Published: 1 June 2018

Abstract

We report on a patient with an adenocarcinoma of the lung harbouring a BRAF V600E mutation who benefited from combination therapy with dabrafenib–trametinib after developing resistance to vemurafenib. To our knowledge, our report shows, for the first time, that combination therapy with dabrafenib–trametinib can overcome vemurafenib resistance in a BRAF V600E–mutated adenocarcinoma of the lung.
Keywords: adenocarcinoma; BRAF; MEK; targeted therapy; acquired resistance; non-small-cell lung cancer; dabrafenib; trametinib adenocarcinoma; BRAF; MEK; targeted therapy; acquired resistance; non-small-cell lung cancer; dabrafenib; trametinib

Share and Cite

MDPI and ACS Style

Schmid, T.; Buess, M. Overcoming Resistance in a BRAF V600e–Mutant Adenocarcinoma of the Lung. Curr. Oncol. 2018, 25, 217-219. https://doi.org/10.3747/co.25.3936

AMA Style

Schmid T, Buess M. Overcoming Resistance in a BRAF V600e–Mutant Adenocarcinoma of the Lung. Current Oncology. 2018; 25(3):217-219. https://doi.org/10.3747/co.25.3936

Chicago/Turabian Style

Schmid, T., and M. Buess. 2018. "Overcoming Resistance in a BRAF V600e–Mutant Adenocarcinoma of the Lung" Current Oncology 25, no. 3: 217-219. https://doi.org/10.3747/co.25.3936

APA Style

Schmid, T., & Buess, M. (2018). Overcoming Resistance in a BRAF V600e–Mutant Adenocarcinoma of the Lung. Current Oncology, 25(3), 217-219. https://doi.org/10.3747/co.25.3936

Article Metrics

Back to TopTop